[Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes].
Chatenoud
Lucienne
L
Inserm U.580, Université René Descartes, Paris 5, Hôpital Necker-Enfants Malades, France. chatenoud@necker.fr
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology*; D017322:Clinical Trials, Phase II as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance
D000911:Antibodies, Monoclonal; D017252:CD3 Complex